doi: 10.1016/j.nut.2021.111153 256 ZhuCZhangSSongCZhangYLingQHoffmannPRet al
However, it is important to note the heterogeneity observed in some of the outcomes, particularly for BMI and body weight reductions
It would feel cruel and shortsighted to pull coverage for hypertension, diabetes or asthma treatments in the same way that's currently proposed for GLP-1 obesity management medications
Prescribers may suggest several approaches: delaying semaglutide until weaning is complete, reducing breastfeeding frequency to lower medication exposure risk, or exploring non-pharmacological weight loss strategies during nursing
It does not constitute a food, dietary supplement, medicinal product or medical device
Sci Rep 6, 22843, doi: 10.1038/srep22843 (2016)